FARMINGTON, Conn. (PRWEB) November 23, 2020
CytoVeris Inc., an emerging company formed with the vision to change the paradigm in cancer surgery through the introduction of optical-based “guided surgical tools,” today announced the appointment of Mr. Scott Flora to its Advisory team. Currently Board Chair for Palliare Ltd, Conventus Orthopaedics and New View Surgical, Mr. Flora brings to CytoVeris significant knowledge and more than 40 years of medical device experience in implantable devices and surgical instruments.
“We are excited to have Scott join us as a strategic advisor,” said Dr. Alan Kersey, President and CEO of CytoVeris. “We are eager to leverage his extensive industry experience and surgical device domain expertise to pursue our mission of disrupting the current paradigm of breast cancer surgery and improve the lives of cancer patients,”
Mr. Flora has previously held several leadership roles including Interim President and CEO of Invuity, Executive Director of Conventus Orthopaedics, President and CEO of OmniGuide Surgical, President of Covidien's Surgical Device Group and President of Smith & Nephew Orthopedic Reconstruction. He has also served on three public company boards including Invuity, MAKO Surgical and Tengion.
“Our advisors provide invaluable guidance and direction as we pursue our mission at CytoVeris,” commented Mr. Patrick Curry, Chief Operating Officer and Vice President of Finance of CytoVeris. “We are thrilled to welcome Mr. Flora, an accomplished business professional, to this esteemed group and look forward to his guidance.”
Through the introduction of optical “guided surgical tools” that allow for the real-time detection of cancer in an intraoperative setting, CytoVeris is on a mission to change the current paradigm in cancer surgery – ensuring surgeons can remove all cancer in a single surgical procedure. CytoVeris is leveraging the convergence of powerful optical technologies, knowledge of biochemical alteration during carcinogenesis, and explainable artificial intelligence to bring new capabilities into the hands of surgeons, and drive improvements in patient outcomes. We are driven by a passion for science and compassion for cancer patients. For more information, please visit: https://www.cytoveris.com